Mild to Severe Alzheimer's While Residing in an Assisted Living Facility, RUMC

The goal of this open-label study is to test whether donepezil is effective and safe in maintaining memory, behavior, and function in individuals with mild, moderate or severe Alzheimer’s disease residing in assisted living facility.

The study, which is being conducted by the Rush Alzheimer’s Disease Center (one of the 30 sites around the country), is sponsored and funded by Eisai Inc and Pfizer Inc.

Duration of the study is 12 weeks. Eligible subjects will receive donepezil 5mg for six weeks and then 10mg for another six weeks. Subjects who complete the study will be eligible for another 12 weeks of treatment with commercially available Aricept.

Each clinic visit will be a combination of all or some of the following: memory testing, neurological exams, blood draws, ECG recordings, as well as quality of life, neuropsychological and activities of daily living questionnaires.

There will be no cost to people who join the study. The medication and all visits will be covered by the research study.

You may be eligible to participate in this study if you:

Are between 50 and 90 years of age (inclusive)
Have a diagnosis of mild, moderate, or severe Alzheimer’s disease [Mini-Mental State Examination (MMSE) score between 5 and 24, inclusive]
Are not taking a FDA approved medication for Alzheimer’s disease for the last 3 months
Speak English
Have a friend or family member who will accompany the subject to all study visits
Stay in an assisted living facility

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.